ClinicalTrials.gg
CompletedNCT01128595Updated Jan 18, 2017Results posted

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

A Phase 2 interventional study of FF/GW642444M and GW642444M in Asthma, sponsored by GlaxoSmithKline. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
31st of 40
27 · median 102
Started
2010
with 6 others
Phase 2
12 of 40
none open now
Registered
12th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 31st largest by enrollment, is one of 7 that started in 2010, is one of 12 in phase 2, and was the 12th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from allergic triggers in asthma

Read the detailed description

Asthma is an increasingly common disease and is essentially caused by an allergic type of reaction of the immune system. Airways of the lungs become inflamed and narrow as a result of a reaction to triggers like chemicals (house-hold cleaning products, pollution) and allergens (house dust mite and cat or dog fur). The airways become blocked, causing shortness of breath and wheezing. The purpose of this study is to find out more information about how effective the study drugs are at protecting the lungs against allergic triggers of asthma. There are three study drugs being investigated in this study: fluticasone furoate on its own, GW642444M on its own and a combination of fluticasone furoate (FF) and GW642444M.

FF is a corticosteroid that is being developed by for the treatment of asthma. A nasal spray formulation of FF has been approved for marketing in the USA, Europe and Japan for the treatment of hayfever (rhinitis) but the dry powder formulation used in this study is not yet approved.

GW642444M is a long-acting beta2-agonist being developed by GSK for the treatment of chronic obstructive pulmonary disease (COPD). It works by acting on cells in the lungs, causing some of the muscles around the lungs to relax and open up better (bronchodilation), making breathing easier. The combination of FF/GW642444M is being developed as a once-daily treatment for both asthma and COPD.

Study treatment will be taken for 21 days in each period (4 treatment periods: FF alone, GW642444M alone, FF/GW64244M combination and placebo) and each subject will receive all treatments. On D21 subjects will undergo an allergen challenge, followed by a methacholine challenge on D22. The washout between treatment periods will be 21-35 days.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • allergen challenge
  • early asthmatic response
  • mild asthma
  • late asthmatic response
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • within the range 18.5-35.0 kilograms/metre2 (kg/m2).
  • Females of non-child bearing potential.
  • Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation
  • Pre-bronchodilator >70% of predicted at screening
  • Subjects who are current non-smokers
  • Methacholine challenge PC20 \< 8 mg/mL at screening
  • Screening allergen challenge demonstrates that the subject experiences an early asthmatic response

Exclusion criteria

Exclusion Criteria:

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities

    • Subject is hypertensive at screening
    • Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.
    • History of life-threatening asthma
    • Symptomatic with hay fever at screening or predicted to have symptomatic hayfever
    • Unable to abstain from short acting beta agonists
    • Unable to abstain from antihistamines
    • Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-asthma anti-rhinitis or hay fever medication
    • The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months
    • undergoing allergen desensitisation therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Active comparator
    ICS

    Drug: Fluticasone Furoate

  • Active comparator
    ICS/LABA

    Drug: FF/GW642444M

  • Active comparator
    LABA

    Drug: GW642444M

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

    Forced expiratory volume in one second (FEV1) is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen (administered by inhalation) 1 hr after dosing on Day 21. Minimum FEV1 over 4-10 hours post-allergen challenge (minimum LAR) is the minimum value of all of the post-saline time points between 4 and 10 hrs post-allergen challenge, inclusive of the 4 hr and 10 hr timepoints (i.e., minimum over 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs). Absolute change from saline in minimum FEV1 was calculated as the minimum FEV1 minus the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.

    Time frame: Day 21 of each treatment period (up to Study Day 197)

  2. LAR: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hour after dosing on Day 21. LAR FEV1 was measured 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs post-allergen challenge on Day 21. Absolute change from saline in WM FEV1 was calculated as the area under the curve divided by the relevant time interval and subtracting the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.

    Time frame: Day 21 of each treatment period (up to Study Day 197)

  3. Early Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. Minimum FEV1 over 0-2 hrs post-allergen challenge (Minimum EAR) is the minimum value of all of the post-allergen challenge timepoints up to and including 2 hours post-allergen challenge (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, 45 min and 1 hr, 1.5 hrs, and 2 hrs. Absolute change from saline in minimum FEV1 was calculated as the minimum FEV1 minus the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.

    Time frame: Day 21 of each treatment period (up to Study Day 197)

  4. EAR: Absolute Change From Saline in Weighted Mean FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. The EAR FEV1 was measured 0 minutes (min), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 1.5 hrs, and 2 hrs post-allergen challenge on Day 21. Least squares means were obtained by adjusting for period and participant and period Baselines. Absolute change from saline in WM FEV1 was calculated as the area under the curve divided by the relevant time interval and subtracting the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value.

    Time frame: Day 21 of each treatment period (up to Study Day 197)

Secondary outcomes

  1. Maximum Percent Change From Saline in FEV1 Between 0-2 Hrs, Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. FEV1 was measured 0 minutes (min), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 1.5 hrs, and 2 hrs post-allergen challenge on Day 21. Maximum percent change was calculated as the minimum FEV1 minus the saline FEV1 value divided by the saline FEV1 multiplied by 100. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline FEV1 value.

    Time frame: Day 21 of each treatment period (up to Study Day 197)

  2. Provocative Concentration of Methacholine Estimated to Result in a 20% Reduction in FEV1 (PC20) on Day 22 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants inhaled doubling increments of methacholine until a \>=20% fall in FEV1 from the saline value was achieved. After inhalation of saline, 3 measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value.

    Time frame: Day 22 of each treatment period (up to Study Day 198)

07

Results

Posted Aug 9, 2013

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneSequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µgSequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µgSequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo
Started7677
Completed7677
Not completed0000
Washout Period 1
Participant flow — Washout Period 1
MilestoneSequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µgSequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µgSequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo
Started7677
Completed7677
Not completed0000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneSequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µgSequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µgSequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo
Started7677
Completed7677
Not completed0000
Washout Period 2
Participant flow — Washout Period 2
MilestoneSequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µgSequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µgSequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo
Started7677
Completed7677
Not completed0000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneSequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µgSequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µgSequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo
Started7677
Completed7577
Not completed0100
Withdrew: Withdrawal by subject0100
Washout Period 3
Participant flow — Washout Period 3
MilestoneSequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µgSequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µgSequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo
Started7577
Completed7577
Not completed0000
Treatment Period 4
Participant flow — Treatment Period 4
MilestoneSequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µgSequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µgSequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo
Started7577
Completed7577
Not completed0000

Outcome measures

PrimaryLate Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

Forced expiratory volume in one second (FEV1) is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen (administered by inhalation) 1 hr after dosing on Day 21. Minimum FEV1 over 4-10 hours post-allergen challenge (minimum LAR) is the minimum value of all of the post-saline time points between 4 and 10 hrs post-allergen challenge, inclusive of the 4 hr and 10 hr timepoints (i.e., minimum over 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs). Absolute change from saline in minimum FEV1 was calculated as the minimum FEV1 minus the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.

Time frame:
Day 21 of each treatment period (up to Study Day 197)
Reported as:
Least squares mean · Liters
Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
LitersPlaceboFF/VI 100/25 µg ODFF 100 µg ODVI 25 µg OD
Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period-0.731 (-0.878 to -0.584)-0.216 (-0.343 to -0.088)-0.188 (-0.315 to -0.061)-0.536 (-0.676 to -0.396)
Statistical analysis
  • Placebo vs FF/VI 100/25 µg OD · Mean difference (final values): 0.515 · 95% CI 0.330 to 0.701
  • Placebo vs FF 100 µg OD · Mean difference (final values): 0.543 · 95% CI 0.355 to 0.730
  • Placebo vs VI 25 µg OD · Mean difference (final values): 0.195 · 95% CI 0.001 to 0.388
  • FF/VI 100/25 µg OD vs FF 100 µg OD · Mean difference (final values): -0.027 · 95% CI -0.198 to 0.143
  • FF/VI 100/25 µg OD vs VI 25 µg OD · Mean difference (final values): 0.320 · 95% CI 0.140 to 0.501
SecondaryMaximum Percent Change From Saline in FEV1 Between 0-2 Hrs, Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. FEV1 was measured 0 minutes (min), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 1.5 hrs, and 2 hrs post-allergen challenge on Day 21. Maximum percent change was calculated as the minimum FEV1 minus the saline FEV1 value divided by the saline FEV1 multiplied by 100. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline FEV1 value.

Time frame:
Day 21 of each treatment period (up to Study Day 197)
Reported as:
Median · percent change
Maximum Percent Change From Saline in FEV1 Between 0-2 Hrs, Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
percent changePlaceboFF/VI 100/25 µg ODFF 100 µg ODVI 25 µg OD
Maximum Percent Change From Saline in FEV1 Between 0-2 Hrs, Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period-26.13 (-58.9 to -5.4)-10.43 (-58.9 to -2.1)-16.14 (-64.9 to -4.0)-18.35 (-59.3 to -4.4)
SecondaryProvocative Concentration of Methacholine Estimated to Result in a 20% Reduction in FEV1 (PC20) on Day 22 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants inhaled doubling increments of methacholine until a \>=20% fall in FEV1 from the saline value was achieved. After inhalation of saline, 3 measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value.

Time frame:
Day 22 of each treatment period (up to Study Day 198)
Reported as:
Mean · milligrams per milliliter
Provocative Concentration of Methacholine Estimated to Result in a 20% Reduction in FEV1 (PC20) on Day 22 of Each Treatment Period
milligrams per milliliterPlaceboFF/VI 100/25 µg ODFF 100 µg ODVI 25 µg OD
Provocative Concentration of Methacholine Estimated to Result in a 20% Reduction in FEV1 (PC20) on Day 22 of Each Treatment Period1.046 ± 3.31912.500 ± 3.73632.492 ± 5.33710.387 ± 0.5311
PrimaryLAR: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hour after dosing on Day 21. LAR FEV1 was measured 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs post-allergen challenge on Day 21. Absolute change from saline in WM FEV1 was calculated as the area under the curve divided by the relevant time interval and subtracting the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.

Time frame:
Day 21 of each treatment period (up to Study Day 197)
Reported as:
Least squares mean · Liters
LAR: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
LitersPlaceboFF/VI 100/25 µg ODFF 100 µg ODVI 25 µg OD
LAR: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period-0.466 (-0.589 to -0.343)0.018 (-0.089 to 0.125)0.018 (-0.089 to 0.124)-0.298 (-0.415 to -0.181)
Statistical analysis
  • Placebo vs FF/VI 100/25 µg OD · Mean difference (final values): 0.484 · 95% CI 0.332 to 0.636
  • Placebo vs FF 100 µg OD · Mean difference (final values): 0.484 · 95% CI 0.330 to 0.638
  • Placebo vs VI 25 µg OD · Mean difference (final values): 0.168 · 95% CI 0.009 to 0.327
  • FF/VI 100/25 µg OD vs FF 100 µg OD · Mean difference (final values): 0.000 · 95% CI -0.140 to 0.140
  • FF/VI 100/25 µg OD vs VI 25 µg OD · Mean difference (final values): 0.316 · 95% CI 0.168 to 0.464
PrimaryEarly Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. Minimum FEV1 over 0-2 hrs post-allergen challenge (Minimum EAR) is the minimum value of all of the post-allergen challenge timepoints up to and including 2 hours post-allergen challenge (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, 45 min and 1 hr, 1.5 hrs, and 2 hrs. Absolute change from saline in minimum FEV1 was calculated as the minimum FEV1 minus the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.

Time frame:
Day 21 of each treatment period (up to Study Day 197)
Reported as:
Least squares mean · Liters
Early Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
LitersPlaceboFF/VI 100/25 µg ODFF 100 µg ODVI 25 µg OD
Early Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period-1.091 (-1.344 to -0.837)-0.614 (-0.858 to -0.370)-0.826 (-1.070 to -0.581)-0.955 (-1.209 to -0.702)
Statistical analysis
  • FF/VI 100/25 µg OD vs FF 100 µg OD · Mean difference (final values): 0.212 · 95% CI 0.031 to 0.393
  • FF/VI 100/25 µg OD vs VI 25 µg OD · Mean difference (final values): 0.341 · 95% CI 0.147 to 0.536
  • Placebo vs FF/VI 100/25 µg OD · Mean difference (final values): 0.477 · 95% CI 0.282 to 0.672
  • Placebo vs FF 100 µg OD · Mean difference (final values): 0.265 · 95% CI 0.066 to 0.463
  • Placebo vs VI 25 µg OD · Mean difference (final values): 0.135 · 95% CI -0.072 to 0.343
PrimaryEAR: Absolute Change From Saline in Weighted Mean FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. The EAR FEV1 was measured 0 minutes (min), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 1.5 hrs, and 2 hrs post-allergen challenge on Day 21. Least squares means were obtained by adjusting for period and participant and period Baselines. Absolute change from saline in WM FEV1 was calculated as the area under the curve divided by the relevant time interval and subtracting the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value.

Time frame:
Day 21 of each treatment period (up to Study Day 197)
Reported as:
Least squares mean · Liters
EAR: Absolute Change From Saline in Weighted Mean FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
LitersPlaceboFF/VI 100/25 µg ODFF 100 µg ODVI 25 µg OD
EAR: Absolute Change From Saline in Weighted Mean FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period-0.560 (-0.745 to -0.374)-0.297 (-0.476 to -0.118)-0.386 (-0.565 to -0.207)-0.533 (-0.718 to -0.348)
Statistical analysis
  • FF/VI 100/25 µg OD vs FF 100 µg OD · Mean difference (final values): 0.089 · 95% CI -0.037 to 0.215
  • FF/VI 100/25 µg OD vs VI 25 µg OD · Mean difference (final values): 0.236 · 95% CI 0.101 to 0.371
  • Placebo vs FF/VI 100/25 µg OD · Mean difference (final values): 0.263 · 95% CI 0.127 to 0.398
  • Placebo vs FF 100 µg OD · Mean difference (final values): 0.174 · 95% CI 0.036 to 0.312
  • Placebo vs VI 25 µg OD · Mean difference (final values): 0.026 · 95% CI -0.118 to 0.171

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the fourth treatment period (up to Day 210).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/27 (0%)19/27 (70.4%)
FF/VI 100/25 µg OD—0/27 (0%)20/27 (74.1%)
FF 100 µg OD—0/27 (0%)19/27 (70.4%)
VI 25 µg OD—0/26 (0%)22/26 (84.6%)
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPlaceboFF/VI 100/25 µg ODFF 100 µg ODVI 25 µg OD
HeadacheNervous system disorders11/2715/2715/2713/26
NasopharyngitisInfections and infestations2/273/272/275/26
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/273/272/273/26
Seasonal allergyImmune system disorders0/271/273/271/26
DiarrhoeaGastrointestinal disorders1/270/270/272/26
Viral upper respiratory tract infectionInfections and infestations1/272/270/270/26
Oral candidiasisInfections and infestations2/270/270/270/26
ArthralgiaMusculoskeletal and connective tissue disorders0/272/271/270/26
DysmenorrhoeaReproductive system and breast disorders2/270/271/270/26
Upper respiratory tract infectionInfections and infestations1/270/270/271/26

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo, FF/VI 100/25 µg OD, FF 100 µg OD, VI 25 µg
Mean30.8 ± 7.46
Gender
Gender(Participants)Placebo, FF/VI 100/25 µg OD, FF 100 µg OD, VI 25 µg
Female8
Male19
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo, FF/VI 100/25 µg OD, FF 100 µg OD, VI 25 µg
White/Caucasian/European Heritage25
East Asian Heritage1
Mixed Race1
08

Study locations

4 sites
  • GSK Investigational Site
    Randwick, New South Wales 2031, Australia
  • GSK Investigational Site
    Wellington, 6021, New Zealand
  • GSK Investigational Site
    Göteborg, SE-413 45, Sweden
  • GSK Investigational Site
    Lund, SE-221 85, Sweden
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 3 months after primary completion. A results delay was requested in Feb 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2010
First posted
May 24, 2010
Start
May 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Results delay requested
Feb 16, 2012
Results first posted
Aug 9, 2013
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01128595
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 24, 2010
Start date
May 2010
Primary completion
May 2011
Completion
May 2011
Results posted
Aug 9, 2013
Last update
Jan 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vilanterol trifenatate · Fluticasone furoate

Start the discussion